BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 36057758)

  • 1. Long-term outcomes of infliximab in patients with Behçet's disease-associated uveitis.
    Yamana S; Hasegawa E; Takeda A; Yawata N; Sonoda KH
    Int Ophthalmol; 2023 Mar; 43(3):937-944. PubMed ID: 36057758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Behçet's disease ocular attack score 24: evaluation of ocular disease activity before and after initiation of infliximab.
    Kaburaki T; Namba K; Sonoda KH; Kezuka T; Keino H; Fukuhara T; Kamoi K; Nakai K; Mizuki N; Ohguro N;
    Jpn J Ophthalmol; 2014 Mar; 58(2):120-30. PubMed ID: 24482146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab therapy in Behçet's uveitis.
    Alizadegan F; Yalcinbayir O; Ucan Gunduz G; Pehlivan Y
    J Fr Ophtalmol; 2022 Nov; 45(9):1036-1041. PubMed ID: 36150991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy of early infliximab-induced remission for refractory uveoretinitis associated with Behçet's disease.
    Keino H; Watanabe T; Nakayama M; Komagata Y; Fukuoka K; Okada AA
    Br J Ophthalmol; 2021 Nov; 105(11):1525-1533. PubMed ID: 32972915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical background comparison of patients with and without ocular inflammatory attacks after initiation of infliximab therapy.
    Yoshida A; Kaburaki T; Okinaga K; Takamoto M; Kawashima H; Fujino Y
    Jpn J Ophthalmol; 2012 Nov; 56(6):536-43. PubMed ID: 23053631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behçet's Disease: National Multicenter Study of 177 Cases.
    Atienza-Mateo B; Martín-Varillas JL; Calvo-Río V; Demetrio-Pablo R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adan A; Hernández MV; Hernández-Garfella M; Valls-Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero-Coma M; Díaz-Llopis M; Gallego R; García-Serrano JL; Ortego-Centeno N; Herreras JM; Fonollosa A; Garcia-Aparicio ÁM; Maíz-Alonso O; Blanco A; Torre-Salaberri I; Fernandez-Espartero C; Jovaní V; Peiteado D; Pato E; Cruz J; Férnandez-Cid C; Aurrecoechea E; García-Arias M; Castañeda S; Caracuel-Ruiz MA; Montilla-Morales CA; Atanes-Sandoval A; Francisco F; Insua S; González-Suárez S; Sanchez-Andrade A; Gamero F; Linares Ferrando LF; Romero-Bueno F; García-González AJ; González RA; Muro EM; Carrasco-Cubero C; Olive A; Prior Á; Vázquez J; Ruiz-Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernandez S; Fernández-Carballido C; Rubio-Romero E; Pages FA; Toyos-Sáenz de Miera FJ; Martinez MG; Díaz-Valle D; López Longo FJ; Nolla JM; Álvarez ER; Martínez MR; González-López JJ; Rodríguez-Cundin P; Hernández JL; González-Gay MA; Blanco R
    Arthritis Rheumatol; 2019 Dec; 71(12):2081-2089. PubMed ID: 31237427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An open-label, prospective, single-arm study of switching from infliximab to cyclosporine for refractory uveitis in patients with Behçet's disease in long-term remission.
    Ida Y; Takeuchi M; Ishihara M; Shibuya E; Yamane T; Hasumi Y; Kawano S; Kimura I; Mizuki N
    Jpn J Ophthalmol; 2021 Nov; 65(6):843-848. PubMed ID: 34586526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet's disease: a multicenter study.
    Takeuchi M; Kezuka T; Sugita S; Keino H; Namba K; Kaburaki T; Maruyama K; Nakai K; Hijioka K; Shibuya E; Komae K; Hori J; Ohguro N; Sonoda KH; Mizuki N; Okada AA; Ishibashi T; Goto H; Mochizuki M
    Ophthalmology; 2014 Oct; 121(10):1877-84. PubMed ID: 24950593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab for uveitis of Behçet's syndrome: a trend for earlier initiation.
    Guzelant G; Ucar D; Esatoglu SN; Hatemi G; Ozyazgan Y; Yurdakul S; Seyahi E; Yazici H; Hamuryudan V
    Clin Exp Rheumatol; 2017; 35 Suppl 108(6):86-89. PubMed ID: 29148418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Behçet's disease ocular attack score 24 and visual outcome in patients with Behçet's disease.
    Tanaka R; Murata H; Takamoto M; Ohtomo K; Okinaga K; Yoshida A; Kawashima H; Nakahara H; Fujino Y; Kaburaki T
    Br J Ophthalmol; 2016 Jul; 100(7):990-994. PubMed ID: 26553921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ten-Year Retention Rate of Infliximab in Patients with Behçet's Disease-Related Uveitis.
    Fabiani C; Sota J; Vitale A; Emmi G; Vannozzi L; Bacherini D; Lopalco G; Guerriero S; Venerito V; Orlando I; Franceschini R; Fusco F; Frediani B; Galeazzi M; Iannone F; Tosi GM; Cantarini L
    Ocul Immunol Inflamm; 2019; 27(1):34-39. PubMed ID: 29099660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 10-year follow-up of infliximab monotherapy for refractory uveitis in Behçet's syndrome.
    Horiguchi N; Kamoi K; Horie S; Iwasaki Y; Kurozumi-Karube H; Takase H; Ohno-Matsui K
    Sci Rep; 2020 Dec; 10(1):22227. PubMed ID: 33335139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the Treatment Results for Behçet Uveitis in Patients Treated with Infliximab and Interferon.
    Yalçindag N; Köse HC
    Ocul Immunol Inflamm; 2020; 28(2):305-314. PubMed ID: 31268743
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term Follow-up and Optimization of Infliximab in Refractory Uveitis Due to Behçet Disease: National Study of 103 White Patients.
    Martín-Varillas JL; Atienza-Mateo B; Calvo-Rio V; Beltrán E; Sánchez-Bursón J; Adán A; Hernández-Garfella M; Valls-Pascual E; Sellas-Fernández A; Ortego N; Maíz O; Torre I; Fernández-Espartero C; Jovani V; Peiteado D; Valle DD; Aurrecoechea E; Caracuel MA; García-González AJ; Álvarez ER; Vegas-Revenga N; Demetrio-Pablo R; Castañeda S; González-Gay MA; Hernández JL; Blanco R;
    J Rheumatol; 2021 May; 48(5):741-750. PubMed ID: 33004539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Follow-up of Patients with Behçet Uveitis after Discontinuation of Infliximab Therapy.
    Köse HC; Yalçındağ N
    Ocul Immunol Inflamm; 2022 Jan; 30(1):203-207. PubMed ID: 32779960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Infliximab for Early Remission Induction in Refractory Uveoretinitis Associated with Behçet Disease: A 2-year Follow-up Study.
    Keino H; Okada AA; Watanabe T; Nakayama M; Nakamura T
    Ocul Immunol Inflamm; 2017 Feb; 25(1):46-51. PubMed ID: 27767359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adalimumab for treatment of severe Behçet's uveitis: a retrospective long-term follow-up study.
    Interlandi E; Leccese P; Olivieri I; Latanza L
    Clin Exp Rheumatol; 2014; 32(4 Suppl 84):S58-62. PubMed ID: 25005224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet's disease: results of a multicentre open-label study.
    Santos-Gómez M; Calvo-Río V; Blanco R; Beltrán E; Mesquida M; Adán A; Cordero-Coma M; García-Aparicio ÁM; Valls Pascual E; Martínez-Costa L; Hernández MV; Hernandez Garfella M; González-Vela MC; Pina T; Palmou-Fontana N; Loricera J; Hernández JL; González-Gay MA
    Clin Exp Rheumatol; 2016; 34(6 Suppl 102):S34-S40. PubMed ID: 27054359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparisons of Clinical Features in Japanese Patients with Behçet's Uveitis Treated in the 1990s and the 2000s.
    Nakahara H; Kaburaki T; Tanaka R; Yoshida A; Takamoto M; Kawata M; Fujino Y; Kawashima H; Aihara M
    Ocul Immunol Inflamm; 2020; 28(2):262-269. PubMed ID: 30806114
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-term efficacy of infliximab treatment and the predictors of treatment outcomes in patients with refractory uveitis associated with Behçet's disease.
    Ueda S; Akahoshi M; Takeda A; Inoue Y; Omoto A; Ayano M; Kimoto Y; Mitoma H; Arinobu Y; Niiro H; Tsukamoto H; Horiuchi T; Hikita SI; Fukuhara T; Ishibashi T; Sonoda KH; Akashi K
    Eur J Rheumatol; 2018 Mar; 5(1):9-15. PubMed ID: 30501852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.